title: P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo.
abstract: We examined whether the increased expression of P-glycoprotein (P-gp) encoded by the human multidrug resistance gene MDR1 is related to the acquired multidrug resistance of lung cancer in vivo. We estimated the chemosensitivity of lung cancer xenografts (LC-6, adenocarcinoma; Lu-24, small-cell cancer) by calculation of relative tumour growth (T/C%, treated/control) in vivo, based on statistical significance determined by the Mann-Whitney U test (P < 0.01, one-sided). MDR1 gene expression levels were evaluated by reverse transcription-polymerase chain reaction (RT-PCR) assay. P-gp production and P-gp localisation were examined by Western blotting and by immunohistochemical analysis respectively. LC-6 and Lu-24 were initially sensitive to both vincristine (VCR, 1.6 mg kg-1: LC-6, 45%; Lu-24, 39%) and doxorubicin (DOX, 12 mg kg-1: LC-6, 26%; Lu-24, 27%) in vivo. VCR-resistant variants (LC-6R, 66% and Lu-24R, 68%) selected with VCR (0.4 mg kg-1, x 9) significantly acquired cross-resistance to DOX (LC-6R, 55% and Lu-24R, 55% respectively). RT-PCR assay showed increased levels of MDR1 expression in LC-6R and Lu-24R with stable MDR1 expression levels. P-gp expression levels were elevated, and the percentage of P-gp-positive tumour cells increased in both LC-6R and Lu-24R. These results suggest that P-gp/MDR1 overexpression is related to acquired multidrug resistance in lung cancer in vivo.
authors.affiliation: Department of Pathology, Tokai University School of Medicine, Kanagawa, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Abe
authors.forename: Y
authors.initials: Y
authors.lastname: Ohnishi
authors.forename: M
authors.initials: M
authors.lastname: Yoshimura
authors.forename: E
authors.initials: E
authors.lastname: Ota
authors.forename: Y
authors.initials: Y
authors.lastname: Ozeki
authors.forename: Y
authors.initials: Y
authors.lastname: Oshika
authors.forename: T
authors.initials: T
authors.lastname: Tokunaga
authors.forename: H
authors.initials: H
authors.lastname: Yamazaki
authors.forename: Y
authors.initials: Y
authors.lastname: Ueyema
authors.forename: T
authors.initials: T
authors.lastname: Ogata
authors.forename: N
authors.initials: N
authors.lastname: Tamaoki
authors.forename: M
authors.initials: M
authors.lastname: Nakamura
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000096:biosynthesis*; D000818:Animals; D000951:Antigens, Neoplasm; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D004268:DNA-Binding Proteins; D018432:Drug Resistance, Multiple / Q000502:physiology*; D015972:Gene Expression Regulation, Neoplastic; D019450:Genes, MDR / Q000235:genetics*; D005982:Glutathione Transferase / Q000378:metabolism; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism; D008175:Lung Neoplasms / Q000503:physiopathology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D014407:Tumor Cells, Cultured; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000951:Antigens, Neoplasm; D004268:DNA-Binding Proteins; D007527:Isoenzymes; D014750:Vincristine; D005982:Glutathione Transferase; D004250:DNA Topoisomerases, Type II